Highlights AC Immune SA

Equities

ACIU

CH0329023102

Delayed Nasdaq Other stock markets 01:02:40 2024-04-29 pm EDT			5-day change	1st Jan Change
2.44 ^USD	+3.83%		+0.83%	-51.20%

Mar. 15	AC Immune Files $350 Million Mixed Shelf	MT
Mar. 14	AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Roche terminates licensing agreement with AC Immune	Jan. 22	CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc	Jan. 22	CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases	Jan. 03	CI
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial	Dec. 15	CI
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	23-07-07	RE
AC Immune Receives FDA Fast-Track Designation for Investigational Alzheimer's Treatment; Shares Rise Pre-Bell	23-06-27	MT
AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease	23-06-27	CI
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial	23-01-26	CI
AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development	22-11-30	CI
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-28	CI
AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome	22-10-04	CI
AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC	22-08-02	CI
AC Immune SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-28	CI
AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease	22-06-16	CI
AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology	22-05-09	CI
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AC Immune SA

Equities

ACIU

CH0329023102

Highlights

Filters